Oncotarget Broadens International Cancer Discovery Reporting

On November 20, 2017, oncologist Thomas Bauernhofer at the University Hospital Graz and colleagues from the Institutes for Biophysics and Pathology at the same university in Austria made a discovery that may save thousands of women’s lives. The extraordinary find was reported in Oncotarget.

The researchers were seeking a better understanding of why 30 percent of women who are diagnosed with breast cancer die despite early detection and treatment. The scientists examined biopsy samples from women who were suspected of having breast cancer and found a new biomarker that distinguishes the women who are most likely to die from breast cancer. The biomarker is the GIRK1 protein.

The researcher found two methods of detecting the GIRK1 protein. The discovery introduces the potential for a genetically modified treatment that hinders the protein from expressing itself in breast cancer. There are other systems that are associated with the GIRK1 protein. Those systems may be simpler and easier targets to produce higher survival rates in the 30 percent of women who die due to this protein.

Oncotarget announced that it will publish internationally twice weekly on September 19, 2017. . Oncotarget is a free open access publication that has been publishing on line since 2010. The main concentration of the publication is oncology. The volumes include peer reviewed articles about discoveries in chromosomes, pathology, immunology, aging, microbiology, and autophagy.

Oncotarget has followed the strict structure of the majority of scientific literature. These priorities include a direct object identifier for each paper and the application of COPE standards to all publications. The original idea behind Oncotarget is unique. The publication aims to distribute the latest scientific information as rapidly as possible. Free access allows the less well funded researchers the same opportunity to learn and improve their practice and the health of their patients.

Oncotarget achieved one of its goals by submitting an entire issue to PubMed post online release. The National Library of Medicine assisted Oncotarget in this achievement. Oncotarget is and will be available on EMBASE, PubMed Central, BIOSIS Previews, ISI/Web of Science: Science Citation Index, Biological Abstracts, and Scopus. Oncotarget has the unique ability to publish research from any country in the world. The publication has even featured new advanced methods from countries that usually are not seen in major mainstream publications.

Life Line Screening is Reshaping the Healthcare Sector

The CEOCFO Magazine recently interviewed Dr. Andy Manganaro, the chief medical officer of Life Line Screening about the company and the services it offers. He explained to Lynn Fosse, editor of the magazine that Life Line Screening is the top firm in the U.S. that conducts screening for vascular and their associated diseases.

A recap of Dr. Manganaro’s interview with CEOCFO Magazine

As the CMO of the company, Dr. Manganaro’s role is to supervise the firm’s staff, oversee research, quality assurance, and marketing. He further explained that aside from screening people, Life Line Screening uses a risk algorithm to screen individuals likely to develop cardiovascular diseases. Since the company was established, the services it offers have become increasingly popular among people and physicians. So as to reach a broad clientele, Life Line Screening has developed an innovative marketing campaign that tries to highlight the benefits of screening. According to Dr. Manganaro, Life Line Screening offers a variety of non-invasive testing, such as screening for osteoporosis, ultrasounds for carotid arteries, measurement of ankle brachial index, and EKG screening. This company also provides blood tests for investigating cardiovascular medical conditions. Aside from screening, Life Line Screening also provides counsel on healthy living and ways to prevent the development of vascular diseases and its Twitter.

About Life Line Screening

Life Line Screening was founded in 1993 and is a privately-held company whose headquarters is in Independence, Ohio. This company pioneers in the provision of testing services for medical conditions, such as osteoporosis, atrial fibrillation, aortic aneurysm, diabetes, peripheral arterial, cardiovascular, and heart diseases and learn more about Lifeline Screening.

Life Line Screening employs the latest technology to ensure that their customers get up to date results as well as value for their money. This company works with certified and highly qualified doctors who specialize in various fields of medicine. Life Line Screening also collaborates with the community by providing mass screening activities and more information click here.

These events take place in various settings, including places of worship, neighborhoods, senior centers, corporations, and community centers. This enterprise has more than 5,000 employees who work in the company’s various branches. Some of the professionals who work for this company is Dr. Manganaro, who is a surgeon and an expert in cardiovascular diseases. Dr. Manganaro is also one of the principals of this corporation and its Website.

More visit: http://www.lifelinescreeningwellness.com/

The Ideal Journal for Seeking Medical Answers

Oncotarget is a multidisciplinary medical journal with free access that publishes research papers weekly. It specializes in oncology, immunology, neurotarget, pathology, microbiology, neuroscience, cell death, autophagy, and circadian rhythm. Oncotarget has been publishing medical journals since its founding in 2010. Moreover, it is published by Impact Journals. The editors-in-chief for Oncotarget include Andrei V. Gudkov and Mikhail Blagosklonny from the renowned Roswell Park Cancer Institute.

Learn more: https://www.ncbi.nlm.nih.gov/pmc/journals/1558/

The Aim of Oncotarget

Oncotarget has helped researchers contribute immensely towards the advancement of science. Therefore, the goal of the journal is to have a life without disease. Its mission entails making scientific results readily available for all readers. The journal also aims to maximize the outcome of the research through insightful view; to allow sharing of excellent research results; to eliminate the boundary between different specialties such as oncology and microbiology. Oncotarget aspires to link a variety of biomedical science field as well as fostering basic and clinical science to fight diseases.

Published Samples

Oncotarget published an article describing the diagnostic value and treatment of malignant mesothelioma, asbestos- related disease. The journal pinpointed the method of treating the disease and the results to be expected. Since malignant mesothelioma is poorly responsive to the present cancer treatments, the proper treatment for the disease is microRNAs, small RNAs with diagnostic value in both cancer and pollution exposure.

Oncotarget also published an article concerning EMSY driven suppression, which requires EMSY threonine 207 phospho-sites for DNA damage repair. The journal precisely highlighted that both BRCA1 and BRCA2 were essential for repairing the double strand DNA break. EMSY was recommended to repair the DNA damage by suppressing BRCA2.

The Achievements of Oncotarget

Oncotarget has hit the spotlight because of its constructive, insightful and multiple peer review journals, which has helped authors worldwide to boost the impact f their research. Members of the editorial board who have published different papers include the previous Editor-in-Chief of Cancer Research, Carlo M. Croce, and the Nobel Prize winner, Andrew Schally. Carlo published 27 papers while Andrew published 10 papers. Further, members of Oncotarget/ Gerotarget/Oncoscience were awarded Breakthrough Prize since 2013. These members include Stephen J. Elledge, Bert Vogelstein, Alexander Varshavsky, and Michael N. Hall. Oncotarget is also available on Dove Press.

Avi Weisfogel’s Accomplishments in the Sleep World

Various people in the United States and across the world are affected by sleep disorders, but they have not been diagnosed due to lack of awareness of the condition. In the recent days, medical professionals such as Avi Weisfogel have been conducting extensive research on the problem to determine effective methods for examining and treating the condition. He is the proprietor of various professional medical companies that have been studying sleep conditions.

Avi Weisfogel is a dentist and has been practicing in Old Bridge, New Jersey for about two decades. He noticed about sleep conditions from his patients and gained interest to learn more. In 2010, he founded Healthy Heart Sleep, which has been assisting doctors and patients to better their knowledge on how to treat sleep problems. Dr. Weisfogel holds lectures across the world to educate the medical professionals on how to establish sleep clinics. He also founded another body that is called Dental Sleep Masters. It has been running as from 2015, and his wife is one of its administrators. The agency has been working to determine how dental appliances can be used in the treatment of sleep apnea and Avi on Facebook.

Weisfogel is a passionate about the medical field has made many accomplishments. He holds a BA from the Rutgers University and also got his DDS from the New York University. Avi always conducts research to come up with advanced methods that he can use in treating his patients. His expertise and excellent service enabled him to be named as the Best Dentist in Old Bridge for many consecutive years. He founded a dental clinic that is known as Old Bridge Dental Care in 1999 and has been using it to offer his dentistry services. Medical professions have been referring individuals who need complex dental surgeries to his clinic.

Dr. Weisfogel currently runs a GoFundMe account that he uses in raising funds for Operation Smile. He contributed $5000 to the campaign, and he has been encouraging his friends to donate more. Operations Smile is a charity organization that has been supporting the provision of healthcare to children who come from impoverished backgrounds. He has also been involved in the missions of the foundation and contact him.

Scott Rocklage – A Serious Investor on a Mission

Scott Rocklage became part of 5AM Ventures in 2003 as a venture partner and later in 2004, became one of the managing partner. The Ph D. holder has more than 30 years of experience in health management as well as responsibilities strategic leadership. He has served in different positions of influence including as the CEO and chairman of Cubist Pharmaceuticals as well as the president and CEO of Salutar and Catalytica. He also chaired the board of Relypsa and Novira. He is currently serving as chairman in cidara, Kinestral and Rennovia among others. He has been an executive chair of a number of well-respected boards.

Dr. Scott Rocklage received his B.S in chemistry from the University of California. His chemistry Ph. D is from MIT. He had the opportunity of conducting researches with the 2005 Nobel peace prizewinner Richard Schrock. He has been responsible for patenting or co-patenting more than 30US inventions. He also has over 100 peer-reviewed publications to his name. He currently has an office in Boston MA.

Its name, 5AM is derived from the fact that the company is at its initial formation stage hence its significance. He attributes his success in his business and career life to excellent organization skills as well as proper time management and scheduling habit. He has a harbor of prioritizing the most important tasks first, which has been a major aspect of his company’s success and learn more about Scott.

He believes that focus on people is a great way to achieve success and this is one thing he would do even more if he had a chance to start over. Choosing the right team for a company is an important step from the beginning. He also believes in taking measured risks repeatedly and this is the advice he would give other entrepreneurs. He believes that success in managing your own entrepreneurship venture is the best way to do well in life and not to work for a fortune 500 company and more information click here.

More visit: https://www.crunchbase.com/person/scott-m-rocklage#/entity

Of Oncotarget and its Editors

Oncotarget is a medical journal prepared weekly and covering a broad range of research in oncology. This journal, an Impact publication, was launched in 2010. The chief editors of the journal are Mikhail Blagosklonny and Andrei V. Gudkov.

Mikhail Blagosklonny

Mikhail, a scientist, studies aging alongside cancer. He works at the Roswell Park Cancer Institute in New York as a professor of oncology. He studied at St. Petersburg where he earned both his Master’s degree and his PhD. He studied internal medicine at a master’s level and also experimental medicine on ResearchGate.net at PhD level.

In 2002, he became associate professor at New York Medical College. This position he occupied before proceeding to become a senior scientist in Albany’s Ordway Research Institute on oncotarget.com. In 2009, Mikhail joint Roswell Park Cancer Institute as a professor of oncology.

Mikhail’s research areas include cancer, anti-ageing medication and aging mechanisms: biogerontology. He is a chief editor along with Andrei V. Gudkov.

Andrei V. Gudkov

He is a cancer researcher at http://www.scimagojr.com/journalsearch.php?q=19900191708&tip=sid. He was appointed to the position of Senior VP for basic research. In the department of cell stress biology, he is the senior most person. He is also a senior individual in the National Cancer Institute (NCI). He also holds seniority in the Cancer Centre Support Grant at the Roswell Park Cancer Institute (RPCI).

Since he also holds the position of senior vice president, he is charged with the responsibility of developing strategic plans for scientific programs and enhancing collaboration with national centers of academic excellence. In the past, Dr. Gudkov served in the molecular genetics department at Case Research University where he taught biochemistry.

His experimental oncology doctoral degree was earned from USSR’s Cancer Research Centre. He has also studied molecular biology in USSR’s Moscow University. He holds about 27 patents and is an author of 135 scientific articles.

Mission

Oncotarget is a weekly multi disciplinary journal that can be accessed free. The mission of the journal is to ensure that scientific results are readily available to the public. The journal also aspires to have all discoveries shared in a flash. Indeed, the journal is all about eliminating borders between specialties. Additionally, Oncotarget also aspires to bring together specialties in biomedical science. The journal has since 2010 published 370 papers on the field of oxygen.